The National Center for Advancing Translational Sciences (NCATS) has announced the new members of its Clinical and Translational Science Awards (CTSA) Program steering committee, including Yale School of Medicine Director of Clinical Research and Yale Center for Clinical Investigation (YCCI) Chief Operating Officer Tesheia Johnson, MBA, MHS. The steering committee provides direction to NCATS and the more than 60 CTSA-funded institutions around the country, including Yale.
“Tesheia is a tireless advocate for clinical research both for Yale, and for CTSA sites around the country,” said YCCI Co-Director John Krystal, MD. “Her proven record of leadership at Yale and extensive experience in the effective management of clinical research infrastructure makes her an asset to the CTSA Steering Committee, and ultimately, to the patients who benefit from the innovative therapies that arise from clinical research.”
As director of clinical research at Yale School of Medicine, Johnson plays a key leadership role in the administration of Yale’s CTSA award and its clinical research infrastructure. She is the co-founder, along with community leaders including the African Methodist Episcopal Zion (AME Zion) Churches of Connecticut and Junta for Progressive Action, of the Yale Cultural Ambassadors program, launched more than 10 years ago to catalyze the sustainable advancement of patient diversity, equity, and inclusion in clinical research. Johnson was elected to the CTSA Steering Committee as an administration member. Her three-year appointment began January 1, 2022.
“I am thrilled Tesheia will be representing our Yale CTSA. Since the award of the CTSA program in 2006, she has been a driving force, not only in the area of clinical trial diversity, but also in administrative innovation, in the areas of clinical trials recruitment, EHR-CTMS integration, and evaluation,” said YCCI Co-Director Brian Smith, MD. “The administrative and clinical transformation she has helped us to achieve here at Yale have been adopted by other centers nationally and internationally. She will be a wonderful addition to the CTSA National Consortium Steering Committee.”
The NCATS CTSA Program Steering committee provides leadership for sharing of policies, practices, and resources, for the program’s CTSA sites. The committee will identify and recommend best practices and policies to advance clinical and translational research as a discipline, and facilitate collaboration among CTSA Program and non-CTSA Program institutions, and partners in clinical and translational research, such as industry, laboratories, and hospitals.
“I am honored to be appointed to the CTSA Steering Committee, and am looking forward to collaborating with other committee members to carry out the mission of NCATS to advance translational research and facilitate the work of devoted investigators to development new interventions for patients everywhere,” says Johnson.